Chinese corporate earnings have shown significant growth, providing investors with insights into promising stock sectors, according to Goldman Sachs. Nearly half of the constituents of the MSCI China index surpassed earnings estimates in the second quarter, driven predominantly by the information technology and healthcare sectors. Goldman Sachs’ latest analysis indicates that earnings for Chinese stocks grew at a remarkable 24% year-over-year during the second quarter, marking the highest quarterly growth rate in five years, up from just 6% in the first quarter.
The surge in earnings is largely attributed to companies involved in artificial intelligence. As the focus on AI-related stocks intensifies globally, many investors are shifting their attention toward untapped growth areas beyond traditional hardware and semiconductor sectors. Transcripts from earnings calls of over 1,500 Chinese companies reveal that discussions have expanded to cover various downstream sectors, including data center operations, AI models, automotive applications, and healthcare.
To identify potential high-performing stocks, Goldman Sachs screened its buy-rated coverage for Chinese companies projected to achieve over 15% annual earnings growth through 2027 and a recent median increase in earnings per share estimates of 7%. Notably, healthcare stocks, particularly in pharmaceuticals, featured prominently in this analysis, comprising one-third of the selected companies. Among them, Innovent Biologics, listed in Hong Kong, is anticipated to see its earnings more than double in the coming year, while other companies, including BeOne Medicines and CSPC, also forecast substantial growth.
Goldman Sachs anticipates an overall 8% earnings growth for the MSCI China index in 2023, which contrasts sharply with the broader consensus expectation of 17%.
Why this story matters
- Investors are identifying emerging sectors that may yield higher returns as traditional AI stocks become saturated.
Key takeaway
- Substantial earnings growth in sectors like healthcare indicates potential for future investment opportunities in the Chinese market.
Opposing viewpoint
- The conservative earnings projection by Goldman Sachs contrasts with the more optimistic consensus, which could suggest varying market outlooks.
